IRONWOOD PHARMACEUTICALS INC — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Ironwood raised full-year 2026 U.S. LINZESS net sales guidance from $1.15–$1.20B to $1.20–$1.25B (35%+ YoY growth), total revenue from $460–$485M to $485–$510M, and adjusted EBITDA from $310M to >$350M. Q3 2026: LINZESS U.S. net sales $325M (3.2% YoY), total revenue $133M, GAAP net income $60M, adjusted EBITDA $98M. Year-to-date 2026 U.S. LINZESS sales of $880M already exceed full 2025 total.
Why this rating
LINZESS represents ~70% of revenue; $1.20–$1.25B guidance is ~5x company market cap, material to near-term trajectory and cash generation.
Tradability signal
NO TRADE
No trade: positive news with only +0.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.01% over 4 hrs, n=365). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.13 ▼ 1.27% | at our read · unknown $4.18 | +10 min · unknown $4.30 ▲ 2.80% | +30 min · unknown $4.26 ▲ 1.84% | +1 hr · unknown $4.12 ▼ 1.51% | +4 hrs · unknown $3.87 ▼ 7.51% |
The stock had already moved +1.28% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.